383 results about "Nervous system disease" patented technology

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

The invention discloses a nervous system disease auxiliary evaluation method based on a large model and related equipment. The method comprises the following steps: constructing a structured knowledge graph based on multi-modal heterogeneous data of nervous system disease guide texts, symptom descriptions and examination results; a graph neural network module is embedded based on the structured knowledge graph in combination with a large language model, an inference network model of a dynamic graph structure is generated, and a dynamic diagnosis path tree is formed by calculating the relation weight between the medical nodes in the graph; and generating interpretable diagnosis suggestions through the reasoning network model according to the current symptom description, the examination result and the historical medical history of the patient. The problems that an existing model still has obvious bottlenecks and clinical challenges, depends on single modal data, is insufficient in quantification of dynamic signs such as a reasoning level, tremor frequency and gait abnormity, does not achieve disease development time sequence modeling and is difficult in clinical conversion can be solved.

The invention discloses application and a preparation method of exosome EGF-FGF-EXO containing double growth factors, the exosome EGF-FGF-EXO is uniform in particle size, high in loading efficiency and good in biological activity, the double growth factors comprise an epidermal growth factor EGF and a fibroblast growth factor FGF, and the epidermal growth factor EGF and the fibroblast growth factor FGF are added into the exosome EGF-FGF. The preparation method of the exosome EGF-FGF-EXO comprises preparation of an induced pluripotent stem cell (iPSC) exosome and loading of EGF-FGF, a recombinant epidermal growth factor (EGF) and a fibroblast growth factor (FGF) are loaded on the exosome from iPS-clone 12c, and the exosome product which has high biological activity and is used for treating nervous system diseases of neuroinflammation is prepared. The invention develops a brand new technical path for treatment of nervous system diseases, and in the fields of epilepsy, neurodegenerative diseases, brain injury and the like, the life quality of patients can be improved and important theoretical basis and technical support can be provided for precise medical treatment of nervous system diseases by precisely regulating and controlling neuroinflammation.

The invention discloses a nervous system image analysis method and a nervous system image analysis device, and relates to the technical field of nervous system disease diagnosis and treatment. Fusing and collecting multi-modal data: collecting nervous system image data of functional magnetic resonance imaging (fMRI), magnetic resonance spectrum imaging (MRS), diffusion tensor imaging (DTI) and positron emission tomography (PET) modals of a patient through an internal system of a hospital; according to the method, multi-modal data of functional magnetic resonance imaging, magnetic resonance spectrum imaging, diffusion tensor imaging and positron emission tomography are integrated, quality evaluation and integration processes are executed in the central data processing unit, the accuracy and reliability of the data are remarkably enhanced, meanwhile, a space-time joint feature analysis model is introduced, and the accuracy and reliability of the data are improved. The time and space dimension information in the image data is linked, the change rule and internal correlation of the data in the time and space dimensions are mined, and the diagnosis accuracy of nervous system diseases is improved.

The invention discloses application of a small molecule compound in preparation of a product for treating nervous system diseases. According to the application disclosed by the invention, it is determined for the first time that Chebulinic acid and 1, 1, 1-Kestohexenose are targeted PU.1 inhibitors, nerve cell activity decline caused by A beta deposition can be improved, and a new technical choice is provided for developing a treatment method for nerve injury diseases and protecting or improving nerve cell injury.

Provided herein are elastin-like polypeptides, endosomal escape peptides, and compounds comprising an elastin-like polypeptide chemically or recombinantly conjugated to one or more endosomal escape peptides. Also provided herein are compositions comprising a compound provided herein and an agent, methods of delivering an agent, and methods of treating or preventing a disease (e.g., a cardiovascular disease, a lung or respiratory disease, a musculoskeletal disease, a hematological disease, an immune disorder, an infectious disease, a genetic disease, cancer, a neurological disease, a psychiatric disorder, a metabolic disorder, or an inflammatory disease).

The invention relates to a device for risk assessment of nervous system diseases, and a processor of the device is configured to receive eye movement data and electroencephalogram data which are associated in a time sequence, and fuse a double-branch deep neural network in a model through multiple modes to assess the risk of the nervous system diseases, performing feature extraction and attention mechanism-based cross-modal feature fusion on the eye movement data and the electroencephalogram data to obtain cross fusion features; and outputting risk assessment results and risk assessment parameters of at least one type of nervous system diseases through an output layer of the multi-modal fusion assessment model. According to the method and the device, the problem that diagnosis sensitivity and universality are insufficient due to the fact that diagnosis only depends on a single information source in related technologies is solved, disease features can be more comprehensively constructed from two levels of neural activity and behavior response by fusing data of two modes of eye movement and electroencephalogram, parallel diagnosis is further performed for multiple types of diseases, and the diagnosis efficiency is improved. The sensitivity and applicability of neuropsychiatric diagnosis are improved, and particularly, the method has more remarkable accuracy in early stages such as mild cognitive impairment and the like.

The invention discloses a quantitative detection method for sweat gland cholinergic nerves of a neuron intracellular inclusion body disease. Belongs to the technical field of biological science. Performing immunohistochemical staining; scanning a slide; and calculating the density of the cholinergic nerve fiber. The invention relates to a simple and feasible method for quantitatively evaluating cholinergic nerve fibers of a neuron intracellular inclusion body disease. The method comprises the following steps: carrying out skin biopsy on control receptors of a neuron intranuclear inclusion body disease and a nervous system-free disease, slicing, carrying out immunofluorescent staining by using a VIP antibody, quantitatively calculating the density of cholinergic nerve fibers labeled by the sweat gland VIP antibody in dermis by using Image J software, analyzing whether the cholinergic nerve fibers have differences in the two groups of receptors, and if so, determining whether the cholinergic nerve fibers have differences in the two groups of receptors. Evaluating the nervous injury and severity of the cholinergic nerve; the invention provides a new way for accurately evaluating the autonomic nerve injury and severity of the neuronal intracellular inclusion body disease.

The invention belongs to the technical field of drug development, and particularly relates to application of 2-fluoro-N-(2-(4-methyl-2-(m-tolyl) thiazole-5-yl) ethyl) benzenesulfonamide in preparation of drugs for treating nervous system diseases. The invention aims to provide a medicine which has small toxic and side effects and can target SLC11A2 to treat or improve nerve cell injury. According to the technical scheme, the invention relates to application of 2-fluoro-N-(2-(4-methyl-2-(m-tolyl) thiazole-5-yl) ethyl) benzenesulfonamide in preparation of a medicine for treating nervous system diseases. It is proved that the compound 2-fluoro-N-(2-(4-methyl-2-(m-tolyl) thiazole-5-yl) ethyl) benzenesulfonamide is small in toxic and side effect, and nerve cell damage can be protected or improved by targeting SLC11A2; and a new choice is provided for treating or improving nerve cell injury.

Described herein are neuroactive steroids of the Formula (II): or a pharmaceutically acceptable salt thereof; wherein A, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5, R6 and are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use and treatment, e.g., such for inducing sedation and / or anesthesia.

Novel compounds that act as antagonists to human GPR39 protein are disclosed. Pharmaceutical compositions and methods of use for antagonists to human GPR39 protein are disclosed. In particular, methods of using the antagonists in the treatment of diseases or conditions including cardiovascular conditions, endocrine system and hormone disorders, cancer disorders, metabolic diseases, gastrointestinal and liver diseases, hematological disorders, neurological disorders and respiratory diseases are disclosed herein.

The invention belongs to the technical field of biological medicine, and relates to application of an OXTR agonist in preparation of a medicine for treating chronic sinusitis (CRS) and respiratory ciliary injury. CRS is treated based on targeted OXTR, and it is found that the OXTR agonist has an excellent treatment effect on promotion of nasal mucosa cilia regeneration and improvement of chronic sinusitis and can promote cilia repair, reduce infiltration of neutrophils and eosinophils and improve the inflammatory environment. In addition, an intranasal treatment dosage form aiming at OXTR is already applied to clinical application of nervous system diseases, the clinical application range of the medicine is expanded, practical feasibility is achieved by improving a better dosage form, and good industrialization prospects are achieved.

The invention provides a culture method, application and detection method of mesenchymal stem cells for treating nervous system diseases, and belongs to the technical field of biological medicines. The invention provides a culture medium of mesenchymal stem cells, a method for culturing and subculturing the mesenchymal stem cells by using the culture medium, and a method for detecting the biological efficacy of the mesenchymal stem cells for treating nervous system diseases. The mesenchymal stem cell preparation disclosed by the invention has a relatively good treatment effect on nervous system diseases, and can be used for improving the new object recognition capability and the cerebral infarction range, inhibiting the release of inflammatory factors, reducing the oxidative stress level and narrowing the spinal cord lesion range so as to improve nervous system injury.

The invention discloses a nervous system disease teaching and training method and system based on an image recognition technology, and particularly relates to the field of nervous system disease teaching, and the method comprises the steps: obtaining a first dynamic image sequence and interaction behavior data of a user, marking a first dynamic focus segmentation map through an image recognition model, and obtaining a first dynamic focus segmentation map; performing feature comparison operation with a second dynamic image sequence generated by simulation so as to iteratively optimize the image recognition model; and obtaining an interactive feedback operation of the user on the second dynamic image sequence generated by simulation, and analyzing a multi-index evaluation result to generate a personalized learning path plan. According to the nervous system disease teaching and training method and system based on the image recognition technology, a first dynamic focus segmentation map is generated in sequence, automatic labeling is achieved, and the time consumed by manual labeling and case screening is greatly shortened; the dynamic change of the focus in time and space is captured in real time from multiple dimensions, so that the capability of analyzing the dynamic change of the disease is greatly improved.

The invention belongs to the technical field of drug development, and particularly relates to application of (E)-N-benzyl-2-((5-(thiophenyl) furan-2-yl) methylene) hydrazine-1-thioformamide in preparation of drugs for treating nervous system diseases. The invention aims to provide a medicine which has small toxic and side effects and can target SLC11A2 to treat or improve nerve cell injury. According to the technical scheme, the invention relates to application of (E)-N-benzyl-2-((5-(thiophenyl) furan-2-yl) methylene) hydrazine-1-thioformamide in preparation of a medicine for treating nervous system diseases, in particular to application of (E)-N-benzyl-2-((5-(thiophenyl) furan-2-yl) methylene) hydrazine-1-thioformamide. It is proved that the compound (E)-N-benzyl-2-((5-(thiophenyl) furan-2-yl) methylene) hydrazine-1-thioformamide is small in toxic and side effect, and nerve cell damage can be protected or improved by targeting SLC11A2; and a new choice is provided for treating or improving nerve cell injury.

The present invention relates to compounds that inhibit the toxic activity of the extrasynaptic NMDA receptor, in particular by inhibiting the formation of the NMDA receptor / TRPM4 complex. In particular, the present invention relates to diamino compounds according to general formula I and their use in medicine, in particular for the treatment of nervous system diseases, such as neurodegenerative diseases.

The invention relates to the technical field of digital medical treatment, and particularly discloses an artificial intelligence diagnosis system for nervous system diseases. The system comprises a data acquisition module, a preprocessing module, a multi-modal feature extraction module, a feature fusion module, a disease classification module, an interpretability analysis module and a doctor feedback and model updating module. The system supports acquisition and fusion of medical images, electroencephalogram signals, biochemical indexes, questionnaire information and wearable device data, constructs unified feature representation through a weighted attention mechanism, and outputs a prediction result of nervous system diseases based on a deep learning model. And meanwhile, the system is combined with a Shapley value method to realize the interpretability of the diagnosis process, and supports closed-loop return of doctor feedback information and model increment updating. The nervous system disease diagnosis accuracy and early recognition capability are improved, and the method has relatively high clinical deployability and adaptive optimization capability.

The application relates to the field of medicine weighing, in particular to a medicine weighing device for treating nervous system diseases in traditional Chinese medicine, which comprises a supporting seat, a weighing assembly is arranged at the upper end of the supporting seat, a medicine collecting assembly is arranged at the lower end of the supporting seat, a medicine containing assembly is arranged at the upper end of the weighing assembly, a shielding assembly is arranged at the upper end of the supporting seat, the weighing assembly comprises four pressure sensors, the four pressure sensors are fixedly connected to the upper surface of the supporting seat, grooves are arranged on the upper surface of the supporting seat, the four pressure sensors are clamped in the grooves, the fixed bars are driven to move downwards by two air cylinders, the fixed bars drive the shielding columns to move downwards when moving downwards, the shielding columns drive the conical blocks at the upper end to be pulled out from the clamping holes, the through holes and the lower ends of the round holes in sequence, at this moment, the medicine in the conical disc falls along with the clamping holes and the through holes, so that the medicine falls in the medicine disc along the conical blocks, the falling medicine is shielded and protected by the cylinder, and the medicine is prevented from being polluted.

The present invention is in the fields of medicinal chemistry, biotechnology and pharmaceuticals. The invention provides compositions comprising one or more collagen mimetic peptides, optionally attached to one or more therapeutic compounds or one or more imaging compounds, methods for use of such compositions in treating, preventing, ameliorating, curing and / or diagnosing certain diseases and physical disorders in humans and veterinary animals, particularly nervous system diseases, disorders and injuries and cardiovascular system diseases, disorders and injuries. The invention also provides the use of such compositions in treating, preventing, ameliorating, curing and / or diagnosing diseases, disorders and conditions in a variety of other tissues, organs and organ systems. The invention also provides medical devices comprising one or more such compositions of the invention.

Aspects of the present disclosure relate to compositions and methods useful for the treatment of nervous system diseases and disorders. In some embodiments, the disclosure provides methods of treating a nervous system disease or disorder comprising administering both a viral vector comprising an interfering nucleic acid (e.g., an artificial miRNA) and a viral vector comprising a CYP46A1 protein. In some embodiments, the disclosure provides methods of treating Huntington's disease comprising administering both a viral vector comprising an interfering nucleic acid (e.g., an artificial miRNA) targeting the Huntington's gene (HTT) and a viral vector comprising a CYP46A1 protein. In some embodiments, the viral vector comprises a modified viral capsid, for example, for preferentially targeting cells in the CNS or PNS.

Provided is a polypeptide which contains a polypeptide having at least 80%, 85%, 90%, 95%, or 99% identity to amino acid sequence MTYRPGYNPFG (SEQ ID NO: 41) or amino acid sequence AKGYYRPYGVPV (SEQ ID NO: 22), or a polypeptide having one or more amino acid substitutions, deletions and / or additions relative to the amino acid sequence as shown in SEQ ID NO: 41 or 22. The provided polypeptide can interfere with the binding of a Brag2 synaptic protein to the C terminus of an AMPA receptor, thereby inhibiting NMDA-mediated excessive endocytosis of an AMPA receptor and neuronal apoptosis, and playing a role in protecting neuronal cell activity. Therefore, the polypeptide has application prospects and potential development values as a drug for treating nervous system diseases such as strokes, depression, Alzheimer's disease and drug addiction.

The present invention is in the fields of medicinal chemistry, biotechnology and pharmaceuticals. The invention provides compositions comprising one or more collagen mimetic peptides, optionally attached to one or more therapeutic compounds or one or more imaging compounds, for use in methods of treating, preventing, ameliorating, curing and diagnosing certain diseases and physical disorders in humans and veterinary animals, particularly anterior and posterior segment ocular diseases and physical disorders, paraocular and extraocular diseases and physical disorders, and nerve or nervous system diseases and physical disorders, as well as methods of manufacturing such compositions. The invention also provides medical devices comprising one or more such compositions of the invention. The invention also provides methods of use of such compositions and devices in treating and diagnosing certain diseases and physical disorders in humans and veterinary animals, including anterior and posterior segment ocular diseases or disorders, paraocular and extraocular diseases and physical disorders, and nerve or nervous system diseases or disorders.

The invention aims to provide a preparation method of amnion-derived mesenchymal stem cells with high collagen expression. The preparation method comprises the following steps: step 1, reagents and materials: amnion tissues: obtaining a fresh amnion from a healthy puerpera after delivery; the PBS is used for cleaning amniotic tissues; collagenase: type I collagenase, which is used for digesting amniotic tissues to separate mesenchymal stem cells; a cell culture medium is a DMEM / F12 culture medium, and 10% of fetal calf serum and 1% of penicillin-streptomycin double antibodies are added; the transforming growth factor TGF-beta is used for promoting the expression of mesenchymal stem cell collagen; and the fibroblast growth factor FGF can assist in promoting cell proliferation and collagen expression. The invention aims to provide the preparation method of the amniotic membrane-derived mesenchymal stem cells for highly expressing collagen, and the amniotic membrane-derived mesenchymal stem cells can be widely applied to treatment of immune system diseases, reproductive system diseases, skin system diseases, skeletal system diseases, nervous system diseases, digestive system diseases, respiratory system diseases, circulatory system diseases and urinary system diseases. Particularly, the effects of immunosuppression and tissue repair are achieved.

The present invention discloses a nano-thermosensitive assembled gel for nasal administration, a preparation method thereof and its use, namely, mitochondrion-targeted puerarin nanoparticles, a thermosensitive gel, a preparation method thereof and its use. The nano-thermosensitive assembled gel for nasal administration of the present invention uses chitosan modified with SS-31 peptide having mitochondrion-targeting and transmembrane properties as a carrier material, and uses a thioketal cross-linking agent sensitive to reactive oxygen species (ROS) to cross-link the modified chitosan to prepare nanoparticles loaded with puerarin. Through a poloxamer thermosensitive gel system, a thermosensitive nanogel drug reservoir encapsulating the nanoparticles is constructed, and its application in the preparation of drugs for treating nervous system diseases realizes the targeting of the drug to the mitochondria of cerebral ischemic stroke injury, responsive cleavage in an environment rich in ROS, release of the drug, increase of the drug concentration in the mitochondria, and improvement of the brain bioavailability of puerarin, providing a more suitable and effective new dosage form for the treatment of stroke.

The invention relates to the technical field of medicinal chemistry, in particular to lithium valproate and a crystal form, a preparation method, a pharmaceutical composition and application thereof. The crystal forms of the lithium valproate comprise a crystal form I, a crystal form II, a crystal form III, a crystal form IV, a crystal form V, a crystal form VI and a crystal form VII. The lithium valproate provided by the invention has a more comprehensive treatment effect on nervous system diseases, and is good in curative effect and good in stability.

Described herein are therapeutic electrical muscle stimulation (EMS) devices for detecting, diagnosing, treating, or preventing neurological diseases. These devices (including EMS kits, user interfaces and control systems, etc.) and methods may be used as part of a therapeutic or non-therapeutic procedure. For example, these methods and devices may be part of an exercise or fitness and / or may be used as part of a treatment, such as, in particular, for physiotherapy and / or for treating a condition or disease.

The invention belongs to the field of health care products and biological medicines, and particularly discloses an anti-aging stem cell PQQ cordyceps sinensis ganoderma lucidum anthocyanin compound preparation and application thereof.The preparation is composed of apple stem cell extract, PQQ, cordyceps militaris extract, ganoderma lucidum extract, procyanidine and pharmaceutic adjuvants and can be made into capsules or pills or tablets. The preparation method comprises the following steps: extracting the raw material components, uniformly mixing, adding the procyanidine and the auxiliary materials, performing high-pressure homogenization treatment, and finally preparing different dosage forms. Wherein the preparation of the apple stem cell extract, the cordyceps militaris extract and the lucid ganoderma extract comprises detailed steps. The compound preparation can be used for preparing health care products or medicines for preventing / treating senile nervous system diseases, especially medicines for preventing / improving Alzheimer's symptoms. In addition, the invention also provides a pharmaceutical composition containing the compound preparation and an acetylcholin esterase inhibitor.

Disclosed herein are antisense oligonucleotides, such as gapmer antisense oligonucleotides having a modified backbone chemistry (e.g., having one or more spacers), and the like. Such gapmer antisense oligonucleotides with modified backbone chemistry can be used to treat various diseases, such as nervous system diseases and the like.

The invention discloses application of a propanamide derivative in preparation of a medicine for treating nervous system diseases, and belongs to the technical field of medicines, and the propanamide derivative is N-[(6-methoxy-1H-benzimidazole-2-yl) methyl]-3-(pyridine-3-yl) propanamide. The invention discloses the neuroprotection application of the propanamide derivative for the first time by adopting the propanamide derivative to prepare a medicine for treating nervous system diseases, and the protection efficacy of the propanamide derivative is equivalent to that of a positive medicine MK-801.

The invention relates to the field of medicine weighing, in particular to a medicine weighing device for treating nervous system diseases through traditional Chinese medicine, which comprises a supporting seat, a weighing assembly arranged at the upper end of the supporting seat, a medicine collecting assembly arranged at the lower end of the supporting seat, a medicine containing assembly arranged at the upper end of the weighing assembly, and a shielding assembly arranged at the upper end of the supporting seat. The weighing assembly comprises four pressure sensors, the four pressure sensors are fixedly connected to the upper surface of the supporting seat, a groove is formed in the upper surface of the supporting seat, the four pressure sensors are clamped in the groove, two air cylinders drive a fixing strip to move downwards, and the fixing strip drives a shielding column to move downwards when moving downwards. When the shielding column moves downwards, the conical block at the upper end is driven to be pulled out of the lower ends of the clamping hole, the through hole and the round hole in sequence, at the moment, medicinal materials in the conical disc fall down along the clamping hole and the through hole, the medicinal materials fall into the medicine disc along the conical block, and the falling medicinal materials are shielded and protected through the cylinder and prevented from being polluted.